Advertisement
Carbidopa and Levodopa tablets are used in the treatment of Parkinson'sdisease and syndrome. These generic versions of Carbidopa and Levodopa 10 mg /100 mg, 25 mg / 100 mg, and 25 mg / 250 mg tablets are bioequivalent toSinemet(R) tablets distributed by Bristol-Myers Squibb. According to IMS Data,these strengths of Carbidopa and Levodopa had US. sales of approximately $70million for the 12-month period ended June 2008.
Advertisement
Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleasedto add to our product portfolio by launching Carbidopa and Levodopa tabletsimmediately to the marketplace. We continue to focus on working towardsexpanding our product offering as quickly and effectively as possible."
Sinemet(R) is a registered trademark of Merck & Co.
Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops,manufactures, markets and distributes generic and private-labelpharmaceuticals to the nation's largest wholesalers, distributors, drugstorechains and managed care providers.
Safe Harbor: This news release contains forward-looking statements madepursuant to the safe-harbor provisions of the Private Securities LitigationReform Act of 1995. Such statements are based on management's currentexpectations and are subject to risks and uncertainties that could causeactual results to differ materially from those described in theforward-looking statements. These risks and uncertainties are contained in theCorporation's filings with the Securities and Exchange Commission and include,but are not limited to: information of a preliminary nature that may besubject to adjustment, potentially not obtaining or delay in obtaining FDAapproval for new products, governmental restrictions on the sale of certainproducts, development by competitors of new or superior products or cheaperproducts or new technology for the production of products, the entry into themarket of new competitors, market and customer acceptance and demand for newpharmaceutical products, availability of raw materials, timing and success ofproduct development and launches, dependence on few products generatingmajority of sales, product liability claims for which the Company may beinadequately insured, and other risks identified in this report and from timeto time in our periodic reports and registration statements. Theseforward-looking statements represent our judgment as of the date of thisreport. We disclaim, however, any intent or obligation to update ourforward-looking statements.
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
